Effects of regorafenib therapy on health-related quality of life in patients with metastatic colorectal cancer in the phase III CORRECT study

被引：0
|
作者：
Siena, S. [1 ]
Grothey, A. [2 ]
Sobrero, A. [3 ]
Falcone, A. [4 ]
Ychou, M. [5 ]
Lenz, H. J. [6 ]
Yoshino, T. [7 ]
Cihon, F. [8 ]
Pawar, V. [9 ]
Van Cutsem, E. [10 ]
机构：
[1] Osped Niguarda Ca Granda, Milan, Italy
[2] Mayo Clin, Dept Oncol, Rochester, MN USA
[3] Osped San Martino Genova, Genoa, Italy
[4] Univ Pisa, Dept Translat Res & New Technol Med, Pisa, Italy
[5] 1CM Val dAurelle, Montpellier, France
[6] VSC Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA USA
[7] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Chiba, Japan
[8] Bayer HealthCare Pharmaceut, Global Biostat, Montville, NJ USA
[9] Bayer HealthCare Pharmaceut, Global HEOR Specialty Med, Montville, NJ USA
[10] Katholieke Univ Leuven Hosp, Louvain, Belgium
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2156
引用
收藏
页码：S482 / S482
页数：1
相关论文
共 50 条
  • [1] Effects of regorafenib therapy on health-related quality of life in patients with metastatic colorectal cancer in the phase III CORRECT study
    Stein, A.
    Siena, S.
    Grothey, A.
    Sobrero, A.
    Falcone, A.
    Ychou, M.
    Lenz, H. J.
    Yoshino, T.
    Cihon, F.
    Pawar, V.
    van Cutsem, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 40 - 40
  • [2] Effects of regorafenib (REG) therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial
    Chang, Jane
    Ngai, Christopher
    Odom, Dawn
    Radder, Christina
    Kappeler, Christian
    Xu, Rui-hua
    Qin, Shukui
    Kim, Tae Won
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Effects of regorafenib therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.
    Qin, Shukui
    Kim, Tae Won
    Yau, Thomas Cheung
    Ma, Brigette
    Pan, Hongming
    Xu, Jian-Ming
    Bai, Yuxian
    Wang, Liwei
    Yeh, Kun-Huei
    Bi, Feng
    Cheng, Ying
    Tuan Anh Le
    Lin, Jen-Kou
    Liu, Tianshu
    Dong, Ma
    Kappeler, Christian
    Chang, Jane
    Xu, Rui-hua
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [4] Regorafenib dose modifications in patients with metastatic colorectal cancer in the phase III CORRECT study
    Falcone, A.
    Van Cutsem, E.
    Sobrero, A.
    Siena, S.
    Ychou, M.
    Lenz, H. J.
    Yoshino, T.
    Cihon, F.
    Wagner, A.
    Grothey, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S546 - S546
  • [5] Regorafenib dose modifications in patients with metastatic colorectal cancer in the phase III CORRECT study
    Karthaus, M.
    Falcone, A.
    van Cutsem, E.
    Sobrero, A.
    Siena, S.
    Ychou, M.
    Lenz, H. J.
    Yoshino, T.
    Cihon, F.
    Wagner, A.
    Grothey, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 39 - 39
  • [6] Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC)
    Van Cutsem, Eric
    Sobrero, Alberto F.
    Siena, Salvatore
    Falcone, Alfredo
    Ychou, Marc
    Humblet, Yves
    Bouche, Olivier
    Mineur, Laurent
    Barone, Carlo
    Adenis, Antoine
    Tabernero, Josep
    Yoshino, Takayuki
    Lenz, Heinz-Josef
    Goldberg, Richard M.
    Sargent, Daniel J.
    Cihon, Frank
    Wagner, Andrea
    Laurent, Dirk
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] "No problem" health-related quality of life (HRQoL) in patients treated with regorafenib (Reg) for relapsed metastatic colorectal cancer (mCRC).
    Su, Yun
    Ostojic, Helene
    Jaeger, Savina
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients with metastatic colorectal cancer: results of the GERCOR DREAM phase III trial
    Anota, Amelie
    Vernerey, Dewi
    Tournigand, Christophe
    Chibaudel, Benoist
    Samson, Benoit
    Scheithauer, Werner
    Brusquant, David
    Andre, Thierry
    de Gramont, Aimery
    Bonnetain, Franck
    QUALITY OF LIFE RESEARCH, 2016, 25 : 112 - 112
  • [9] Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer
    Karthaus, M.
    Lenz, H-J
    van Cutsem, E.
    Sobrero, A.
    Siena, S.
    Falcone, A.
    Ychou, M.
    Humblet, Y.
    Bouche, O.
    Mineur, L.
    Barone, C.
    Adenis, A.
    Tabernero, J.
    Yoshino, T.
    Goldberg, R. M.
    Cihon, F.
    Wagner, A.
    Grothey, A.
    ONKOLOGIE, 2013, 36 : 70 - 70
  • [10] Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients with metastatic colorectal cancer: Results of the GERCOR DREAM phase III trial.
    Anota, Amelie
    Vernerey, Dewi
    Tournigand, Christophe
    Chibaudel, Benoist
    Samson, Benoit
    Scheithauer, Werner
    Brusquant, David
    Andre, Thierry
    De Gramont, Aimery
    Bonnetain, Franck
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345